Protein Summary
Potential calcium-dependent cell-adhesion protein. May be involved in the establishment and maintenance of specific neuronal connections in the brain. This gene is a member of the protocadherin alpha gene cluster, one of three related gene clusters tandemly linked on chromosome five that demonstrate an unusual genomic organization similar to that of B-cell and T-cell receptor gene clusters. The alpha gene cluster is composed of 15 cadherin superfamily genes related to the mouse CNR genes and consists of 13 highly similar and 2 more distantly related coding sequences. The tandem array of 15 N-terminal exons, or variable exons, are followed by downstream C-terminal exons, or constant exons, which are shared by all genes in the cluster. The large, uninterrupted N-terminal exons each encode six cadherin ectodomains while the C-terminal exons encode the cytoplasmic domain. These neural cadherin-like cell adhesion proteins are integral plasma membrane proteins that most likely play a critica ...more
- ENST00000529619
- ENSP00000433416
- ENSG00000204965
- ENST00000529859
- ENSP00000436557
- ENST00000614258
- ENSP00000484128
- CNRS6
- CNR6
- CNRN6
- CNRS6
- CRNR6
- PCDH-ALPHA5
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
microRNA | 0.93 | ||
cell line | 0.6 | ||
protein domain | 0.58 | ||
small molecule perturbation | 0.49 | ||
pathway | 0.47 | ||
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 0 (req: < 5)
Gene RIFs: 0 (req: <= 3)
Antibodies: 133 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 0 (req: >= 5)
Gene RIFs: 0 (req: > 3)
Antibodies: 133 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 4
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0
Pathways (2)
PathwayCommons (2)
Items per page:
1 – 2 of 2
Data Source | Name | Explore in Pharos | Explore in Source | ||
---|---|---|---|---|---|
PathwayCommons: panther | Cadherin signaling pathway | ||||
PathwayCommons: panther | Wnt signaling pathway | ||||
Name | Explore in Pharos | Explore in Source | ||
---|---|---|---|---|
Cadherin signaling pathway | ||||
Wnt signaling pathway | ||||
Gene Ontology Terms (5)
Functions (1)
Components (1)
Processes (3)
Items per page:
10
1 – 1 of 1
GO Term | Evidence | Assigned by | ||
---|---|---|---|---|
Inferred from Electronic Annotation (IEA) | InterPro | |||
Protein-Protein Interactions (15)
1 – 10 of 15
PCDHA10
Novelty: 1.33333333
p_int: 1
Score: 0.312
Data Source: BioPlex,STRINGDB
DUS2
Family: Enzyme
Novelty: 0.08522727
Score: 0.678
Data Source: STRINGDB
CCDC150
Score: 0.642
Data Source: STRINGDB
TSSK6
Family: Kinase
Novelty: 0.03929405
Score: 0.556
Data Source: STRINGDB
GATAD2A
Novelty: 0.09841585
Score: 0.541
Data Source: STRINGDB
CFAP61
Novelty: 2.47058824
Score: 0.536
Data Source: STRINGDB
PLAA
Family: Enzyme
Novelty: 0.01268726
Score: 0.513
Data Source: STRINGDB
ATCAY
Novelty: 0.08199655
Score: 0.503
Data Source: STRINGDB
ZSCAN31
Family: TF
Novelty: 0.35856574
Score: 0.503
Data Source: STRINGDB
NMRAL1
Novelty: 0.10221465
Score: 0.499
Data Source: STRINGDB
Publication Statistics
PubTator Score 3.5
PubTator score by year
Amino Acid Sequence
Residue Counts
Sequence
MVYSRRGSLGSRLLLLWLLLAYWKAGSGQLHYSIPEEAKHGTFVGRIAQDLGLELAELVPRLFRVASKGR
1-70
GDLLEVNLQNGILFVNSRIDREELCRRRAECSIHLEVIVDRPLQVFHVEVAVKDINDNPPRFSRQEQRLF
70-140
ILESRMPDSRFPLEGASDLDIGANAQLRYRLNPNEYFDLDVKTNEEETNFLELVLRKSLDREETQEHRLL
140-210
VIATDGGKPELTGTVQLLINVLDANDNAPEFDKSIYNVRLLENAPSGTLVIKLNASDADEGINKEIVYFF
210-280
SNLVLDDVKSKFIINSNTGEIKVNGELDYEDYNSYEINIDAMDKSTFPLSGHCKVVVKLLDVNDNTPEMA
280-350
ITTLFLPVKEDAPLSTVIALISVSDRDSGANGQVTCSLMPHVPFKLVSTFKNYYSLVLDSALDRESVSVY
350-420
ELVVTARDGGSPSLWATASVSVEVADVNDNAPAFAQPQYTVFVKENNPPGCHIFTVSARDADAQENALVS
420-490
YSLVERRVGERPLSSYVSVHAESGKVYALQPLDHEEVELLQFQVSARDAGVPPLGSNVTLQVFVLDENDN
490-560
APALLVPRVGGTGGAVSELVPRSVGAGHVVAKVRAVDPDSGYNAWLSYELQPAPGSARIPFRVGLYTGEI
560-630
STTRSLDETEAPRHRLLVLVKDHGEPPLTATATVLVSLVESGQAPKASSRASAGAVGPEAALVDVNVYLI
630-700
IAICAVSSLLVLTLLLYTALRCSAQPTEAVCTRGKPTLLCSSAVGSWSYSQQRRQRVCSGEAPPKTDLMA
700-770
FSPSLPQGPTSTDNPRQPNPDWRYSASLRAGMHSSVHLEEAGILRAGPGGPDQQWPTVSSATPEPEAGEV
770-840
SPPVGAGVNSNSWTFKYGPGNPKQSGPGELPDKFIIPGSPAIISIRQEPTNSQIDKSDFITFGKKEETKK
840-910
KKKKKKGNKTQEKKEKGNSTTDNSDQ
910-936
MVYSRRGSLGSRLLLLWLLLAYWKAGSGQLHYSIPEEAKHGTFVGRIAQDLGLELAELVPRLFRVASKGRGDLLEVNLQNGILFVNSRIDREELCRRRAECSIHLEVIVDRPLQVFHVEVAVKDINDNPPRFSRQEQRLFILESRMPDSRFPLEGASDLDIGANAQLRYRLNPNEYFDLDVKTNEEETNFLELVLRKSLDREETQEHRLLVIATDGGKPELTGTVQLLINVLDANDNAPEFDKSIYNVRLLENAPSGTLVIKLNASDADEGINKEIVYFFSNLVLDDVKSKFIINSNTGEIKVNGELDYEDYNSYEINIDAMDKSTFPLSGHCKVVVKLLDVNDNTPEMAITTLFLPVKEDAPLSTVIALISVSDRDSGANGQVTCSLMPHVPFKLVSTFKNYYSLVLDSALDRESVSVYELVVTARDGGSPSLWATASVSVEVADVNDNAPAFAQPQYTVFVKENNPPGCHIFTVSARDADAQENALVSYSLVERRVGERPLSSYVSVHAESGKVYALQPLDHEEVELLQFQVSARDAGVPPLGSNVTLQVFVLDENDNAPALLVPRVGGTGGAVSELVPRSVGAGHVVAKVRAVDPDSGYNAWLSYELQPAPGSARIPFRVGLYTGEISTTRSLDETEAPRHRLLVLVKDHGEPPLTATATVLVSLVESGQAPKASSRASAGAVGPEAALVDVNVYLIIAICAVSSLLVLTLLLYTALRCSAQPTEAVCTRGKPTLLCSSAVGSWSYSQQRRQRVCSGEAPPKTDLMAFSPSLPQGPTSTDNPRQPNPDWRYSASLRAGMHSSVHLEEAGILRAGPGGPDQQWPTVSSATPEPEAGEVSPPVGAGVNSNSWTFKYGPGNPKQSGPGELPDKFIIPGSPAIISIRQEPTNSQIDKSDFITFGKKEETKKKKKKKKGNKTQEKKEKGNSTTDNSDQ
Find similar targets by: